Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
06/2003
06/12/2003WO2003048298A2 Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048202A2 Nf-kappab activating genes
06/12/2003WO2003048201A1 Antimicrobial bolisin peptides
06/12/2003WO2003047684A2 Method for intracellular modifications within living cells using pulsed electric fields
06/12/2003WO2003047676A1 Techniques for treating neurodegenerative disorders by brain infusion of mutational vectors
06/12/2003WO2003047635A1 Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
06/12/2003WO2003047634A2 Nucleic acids and methods for treating ebv-positive cancers
06/12/2003WO2003047631A2 Clasp-pna-conjugate for the specific transport of nucleic acids which are thermally active
06/12/2003WO2003047616A1 Migration of hematopoietic stem cells and progenitor cells to th e liver
06/12/2003WO2003047613A1 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer
06/12/2003WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism
06/12/2003WO2003047549A2 Post-coated liposome/lipoplex for targeted drug/gene delivery and lipid linked to a delivery, targeting or stabilising moiety
06/12/2003WO2003047532A2 Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
06/12/2003WO2003047525A2 Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
06/12/2003WO2003047524A2 Methods and compositions for modulating the immune system and uses thereof
06/12/2003WO2003047518A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
06/12/2003WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
06/12/2003WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions
06/12/2003WO2002068627A3 Vector constucts
06/12/2003WO2002055692A3 Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
06/12/2003WO2002008389A9 Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
06/12/2003WO2001073133A9 Compositions and methods for identifying and targeting cancer cells
06/12/2003WO2001071007A3 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
06/12/2003WO2000040737A9 High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site
06/12/2003US20030109699 Biopolymers; gene therapy, medical diagnosis
06/12/2003US20030109683 Hybrid proteins; controlling gene expression in gene therapy; Parkinson's disease
06/12/2003US20030109678 Methods and means for regulation of gene expression
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109483 A purified Parapoxvirus ovis envelope protein termed "B2L" can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response
06/12/2003US20030109481 Tumour-cell specific gene expression and its use in cancer therapy
06/12/2003US20030109478 Nucleic acid formulations for gene delivery and methods of use
06/12/2003US20030109477 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
06/12/2003US20030109476 Compositions and methods for the prevention and treatment of Huntington's disease
06/12/2003US20030109475 Introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be introduced into a mammalian host by way of an expression vector either as naked DNA or
06/12/2003US20030109474 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and
06/12/2003US20030109473 One dose vaccination with mycoplasma hyopneumoniae
06/12/2003US20030109472 Replicating adenovirus vectors
06/12/2003US20030109470 Variants thereof, are described wherein a nucleic acid sequence of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed expression of a nucleic acid
06/12/2003US20030109469 Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
06/12/2003US20030109450 Useful in localized transfer of genetic material or proteins. Moreover, the present invention provides methods and compositions for improving and/or controlling wound healing by applying a wound care device comprising HoxD3 and/or HoxA3
06/12/2003US20030109448 Enhancing cellular uptake and redistributing gene regulating polyamides from the extranuclear areas in eukaryotic cells to the nucleus thereof. The method consists of administering to the eukaryotic cells a molecular trafficking compound
06/12/2003US20030109442 Apolipoprotein A-I (ApoA-I), preferably a variant form such as Apolipoprotein A-I Milano (ApoA-IM), alone or more preferably in combination with a lipid carrier such as phospholipids or other drug, can be administered locally
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109042 Stimulant immunology system; cell differentiation; culture product; three-dimensional support
06/12/2003US20030109033 Feline calicivirus genes and vaccines in particular recombinant vaccines
06/12/2003US20030109026 Genetically modified tumor-targeted bacteria with reduced virulence
06/12/2003US20030109022 Asp2
06/12/2003US20030109018 Novel endometriosis-associated gene
06/12/2003US20030109016 Tumor suppresison gene; anticancer agents
06/12/2003US20030109008 Cell proliferation, cell differentiation; stem cells
06/12/2003US20030108984 CD44 splice variant associated with rheumatoid arthritis
06/12/2003US20030108961 Methods and compositions for diagnosing breast cancer
06/12/2003US20030108939 In vivo method for identifying target sites for antisense-mediated inhibition of a selected gene
06/12/2003US20030108923 Blocking gene expression
06/12/2003US20030108920 Tumor suppressor-like proteins that bind IGFBP2
06/12/2003US20030108914 Amplification of nucleic acids
06/12/2003US20030108886 Autogene nucleic acids encoding a secretable RNA polymerase
06/12/2003US20030108880 Gene expression regulation
06/12/2003US20030108596 Lipophilic drug compositions
06/12/2003US20030108562 Administering gag protein; vaccines for human immunodeficiency virus
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108538 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
06/12/2003US20030108531 Genes for transfection into bony tissues
06/12/2003US20030108530 Antisense inhibiting melanoma invasion and functional analogs thereof
06/12/2003US20030108528 Detection of antigens due to injury, disease; promote regeneration of nervous system
06/12/2003US20030108525 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
06/12/2003US20030108523 Controlling proliferation of mesothelioma cells; anticancer agent
06/12/2003US20030108522 Method for using Smad for gene therapy of solid malignant tumors
06/12/2003US20030108521 Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
06/12/2003US20030108517 Membrane-bound cytokine compositions and methods of modulating an immune response using same
06/12/2003CA2468944A1 Migration of hematopoietic stem cells and progenitor cells to the liver
06/12/2003CA2468739A1 Suppression of polymeric alleles
06/12/2003CA2468701A1 T-bet compositions and methods of use thereof
06/12/2003CA2468698A1 Methods and compositions for modulating the immune system and uses thereof
06/12/2003CA2468556A1 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
06/12/2003CA2467073A1 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003CA2465455A1 Compound
06/11/2003EP1317669A2 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
06/11/2003EP1317561A2 Modulation of homologous recombination with single stranded dna binding proteins
06/11/2003EP1317560A1 Self-rearranging dna vectors
06/11/2003EP1317556A1 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
06/11/2003EP1317548A2 Transglutaminase gene products
06/11/2003EP1317536A2 Tnf receptor-like molecules and uses thereof
06/11/2003EP1317532A2 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
06/11/2003EP1317488A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)
06/11/2003EP1317485A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
06/11/2003EP1317471A1 21 human secreted proteins
06/11/2003EP1317470A1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
06/11/2003EP1317469A1 21 human secreted proteins
06/11/2003EP1317468A1 23 human secreted proteins
06/11/2003EP1317289A2 High efficiency cardiac gene transfer
06/11/2003EP1317288A2 Method and composition for treating tumors by selective induction of apoptosis
06/11/2003EP1317275A1 Medicament comprising a dna sequence which codes for the rna-binding koc protein, and comprising a koc protein or a dna sequence of the koc promoter
06/11/2003EP1317273A1 Use of il-6r/il-6 chimera in huntington's disease
06/11/2003EP1317265A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
06/11/2003EP1317258A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
06/11/2003EP1158966B1 Loaded bacterial ghosts as carrier and targeting vehicles
1 ... 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 ... 870